These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27403300)

  • 21. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
    Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of progression of Barrett's esophagus in patients with cirrhosis.
    Apfel T; Lopez R; Sanaka MR; Thota PN
    World J Gastroenterol; 2017 May; 23(18):3287-3294. PubMed ID: 28566888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
    Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
    J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Ma B; Yang S; Li W; Li P
    Front Oncol; 2022; 12():801940. PubMed ID: 35296005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Barrie J; Yanni F; Sherif M; Dube AK; Tamhankar AP
    Surg Endosc; 2021 Aug; 35(8):4756-4762. PubMed ID: 32880012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.
    Picardo SL; O'Brien MP; Feighery R; O'Toole D; Ravi N; O'Farrell NJ; O'Sullivan JN; Reynolds JV
    Dis Esophagus; 2015; 28(2):121-6. PubMed ID: 24428806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review.
    Wani S; Puli SR; Shaheen NJ; Westhoff B; Slehria S; Bansal A; Rastogi A; Sayana H; Sharma P
    Am J Gastroenterol; 2009 Feb; 104(2):502-13. PubMed ID: 19174812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
    Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
    Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A narrative review of Barrett's esophagus in 2020, molecular and clinical update.
    Dam AN; Klapman J
    Ann Transl Med; 2020 Sep; 8(17):1107. PubMed ID: 33145326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.
    Sharma P; Falk GW; Bhor M; Ozbay AB; Latremouille-Viau D; Guerin A; Shi S; Elvekrog MM; Limburg P
    J Health Econ Outcomes Res; 2023; 10(1):51-58. PubMed ID: 36883055
    [No Abstract]   [Full Text] [Related]  

  • 35. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
    Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
    Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
    Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
    Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.
    Yu M; Moinova HR; Willbanks A; Cannon VK; Wang T; Carter K; Kaz A; Reddi D; Inadomi J; Luebeck G; Iyer PG; Canto MI; Wang JS; Shaheen NJ; Thota PN; Willis JE; LaFramboise T; Chak A; Markowitz SD; Grady WM
    Clin Cancer Res; 2022 Sep; 28(17):3761-3769. PubMed ID: 35705525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NON-ENDOSCOPIC ESOPHAGEAL SAMPLING DEVICE AND BIOMARKER PANEL FOR DETECTION OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC).
    Moinova HR; Verma S; Dumot J; Faulx A; Iyer PG; Canto MI; Wang JS; Shaheen NJ; Thota PN; Aklog L; Willis JE; Markowitz SD; Chak A
    medRxiv; 2023 Sep; ():. PubMed ID: 37333176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endoscopic follow-up of Barrett's esophagus: protocol and implications.
    De Looze D
    Acta Gastroenterol Belg; 2000; 63(1):29-35. PubMed ID: 10907316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of Barrett's high-grade dysplasia.
    Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
    Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.